Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspiration Hlt Regulatory News (IHC)

Share Price Information for Inspiration Hlt (IHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.75
Bid: 16.50
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 0.50 (3.03%)
Open: 16.75
High: 16.75
Low: 16.75
Prev. Close: 16.75
IHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution agreement for AIHL test

24 Apr 2020 07:00

RNS Number : 7231K
Genedrive PLC
24 April 2020
 

genedrive plc

("genedrive" or the "Company")

 

Distribution agreement for AIHL test

 

 Inspiration Healthcare to distribute genedrive's Antibiotic Induced Hearing Loss test in UK & Ireland

Option to expand agreement to engage Inspiration Healthcare's global neonatal sub-distributor network

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into a contract for the distribution of the Company's Antibiotic Induced Hearing Loss test (Genedrive® MT-RNR1) in the UK and Ireland with Inspiration Healthcare Group plc (AIM: IHC) ("Inspiration Healthcare"). The companies also expect to expand the scope of the contract over time to engage Inspiration Healthcare's specialty network of over 50 neonatal focussed sub-distributors around the world.

 

David Budd, Chief Executive Officer of genedrive plc, said: "Our agreement with Inspiration Healthcare combines genedrive's innovative first-to-market AIHL product, with a thought leading healthcare company with a specialist emphasis on neonatal care. Inspiration Healthcare has a strong track record in the introduction of new technologies and over many years they have developed an extensive network of key opinion leaders that will be very beneficial as we bring the Genedrive AIHL test to market together."

 

The Genedrive® MT-RNR1 test is the world's first point-of-care genetic test designed for use in a neonatal intensive care setting. The test screens newborns for a genetic mutation called mt-RNR1 that can cause lifelong and irreversible deafness to a child upon administration of certain antibiotics. In the UK, 90,000 babies are admitted to NICU units each year, and 80-85% of them receive antibiotics. Genedrive's rapid genetic test can be completed in less than 30 minutes, allowing for correct treatment decision on antibiotics to be made within one hour of admission, as required by the UK's National Institute of Clinical Excellence (NICE).

 

Neil Campbell, Chief Executive Officer of Inspiration Healthcare, commented: "We are delighted to be able to work with genedrive plc with this novel testing device for new born babies that could suffer hearing loss due to antibiotics given to them on admission into neonatal intensive care. Our focus has always been products that can have a profound effect on the patient outcome and we look forward to working with genedrive to make this test the standard of care in the UK and the wider neonatal community around the world."

 

genedrive plc

 

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

finnCap Ltd

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, Antibiotic Induced Hearing Loss, and has tests in development for tuberculosis (mTB) and SARS-CoV-2.

 

About Inspiration Healthcare (http://www.inspiration-healthcare.com)

 

Inspiration Healthcare is a global provider of medical technology for use in critical care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

 

Through investment in research and development the Company has 6 key own brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally the Company has its own range of products for maintaining normothermia pre- during and post-surgery.

 

With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe. In the UK and Ireland the Company has a direct sales team selling Inspiration Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGREAELDAASEEAA
Date   Source Headline
1st May 20247:00 amRNSTrading update
9th Apr 20247:00 amRNSGrant of Options under Sharesave Scheme
1st Feb 202411:33 amRNSGrant of Covenant Waiver
31st Jan 20247:00 amRNSTrading update
18th Jan 20247:00 amRNSMDSAP certification
15th Jan 20243:04 pmRNSDirector/PDMR Shareholding
4th Jan 20247:00 amRNSStrategic acquisition of Airon Corporation
7th Dec 20237:00 amRNSDirectorate Change
2nd Nov 20237:00 amRNSLaunch of SLE1500 Non-Invasive Ventilator
31st Oct 202310:18 amRNSHolding(s) in Company
17th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
12th Oct 20237:00 amRNSShareSoc investor presentation
3rd Oct 20237:00 amRNSHalf-year Report
22nd Sep 20237:00 amRNSInvestor results presentation
31st Aug 20237:00 amRNSTrading update
12th Jul 202310:45 amRNSHolding(s) in Company
10th Jul 20237:00 amRNSChange of Registered Office
27th Jun 202312:20 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement
22nd Jun 20237:00 amRNSAppointment of Non-Executive Director
13th Jun 20232:00 pmRNSInvestor presentation
12th Jun 20237:00 amRNSCFO appointment
9th Jun 20237:00 amRNSGrant of Options
5th Jun 20235:13 pmRNSHolding(s) in Company
5th Jun 20237:00 amRNSHolding(s) in Company
2nd Jun 20237:00 amRNSNotice of AGM and posting of Annual Report
1st Jun 20233:27 pmRNSAIM Rule 17 Schedule Two (g) Update
1st Jun 20238:55 amRNSHolding(s) in Company
24th May 20237:00 amRNSAppointment of Nominated Adviser and Broker
17th May 20237:00 amRNSMello investor conference
4th May 20237:00 amRNSInvestor Day
3rd May 20237:00 amRNSFinal Results
6th Apr 20235:53 pmRNSGrant of Options
3rd Apr 20235:53 pmRNSGrant of Options
31st Mar 20236:27 pmRNSExercise of Options & Issue of Equity
23rd Mar 20237:00 amRNSLaunch of range extension of neonatal ventilators
1st Mar 20237:00 amRNSChange of Website
17th Feb 20232:05 pmRNSTR1 Notification
16th Feb 20237:00 amRNSTrading Update
9th Dec 20222:27 pmRNSTR1 Notification
8th Dec 20221:10 pmRNSTR1 Notification
5th Dec 20227:00 amRNSBoard Changes
30th Nov 202210:28 amRNSDirector / PDMR Dealing
28th Nov 20222:05 pmRNSSecond Price Monitoring Extn
28th Nov 20222:00 pmRNSPrice Monitoring Extension
28th Nov 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.